1058 related articles for article (PubMed ID: 21376385)
1. Eribulin monotherapy versus treatment of physician's choice in patients with metastatic breast cancer (EMBRACE): a phase 3 open-label randomised study.
Cortes J; O'Shaughnessy J; Loesch D; Blum JL; Vahdat LT; Petrakova K; Chollet P; Manikas A; Diéras V; Delozier T; Vladimirov V; Cardoso F; Koh H; Bougnoux P; Dutcus CE; Seegobin S; Mir D; Meneses N; Wanders J; Twelves C;
Lancet; 2011 Mar; 377(9769):914-23. PubMed ID: 21376385
[TBL] [Abstract][Full Text] [Related]
2. A randomized, open-label, multicenter, phase 3 study to compare the efficacy and safety of eribulin to treatment of physician's choice in patients with advanced non-small cell lung cancer.
Katakami N; Felip E; Spigel DR; Kim JH; Olivo M; Guo M; Nokihara H; Yang JC; Iannotti N; Satouchi M; Barlesi F
Ann Oncol; 2017 Sep; 28(9):2241-2247. PubMed ID: 28911085
[TBL] [Abstract][Full Text] [Related]
3. Efficacy of eribulin in women with metastatic breast cancer: a pooled analysis of two phase 3 studies.
Twelves C; Cortes J; Vahdat L; Olivo M; He Y; Kaufman PA; Awada A
Breast Cancer Res Treat; 2014 Dec; 148(3):553-61. PubMed ID: 25381136
[TBL] [Abstract][Full Text] [Related]
4. Efficacy and safety of eribulin mesylate in patients with locally advanced or metastatic breast cancer previously treated with anthracycline/taxanes.
Chen L; Yan X; Luo T; Tian T; He P; Zhong X
Cancer Med; 2024 May; 13(10):e7295. PubMed ID: 38785215
[TBL] [Abstract][Full Text] [Related]
5. Phase II study of eribulin mesylate (E7389) in patients with metastatic castration-resistant prostate cancer stratified by prior taxane therapy.
de Bono JS; Molife LR; Sonpavde G; Maroto JP; Calvo E; Cartwright TH; Loesch DM; Feit K; Das A; Zang EA; Wanders J; Agoulnik S; Petrylak DP
Ann Oncol; 2012 May; 23(5):1241-1249. PubMed ID: 21903605
[TBL] [Abstract][Full Text] [Related]
6. Effectiveness and safety of eribulin in Japanese patients with HER2-negative, advanced breast cancer: a 2-year post-marketing observational study in a real-world setting.
Inoue K; Takahashi M; Mukai H; Yamanaka T; Egawa C; Sakata Y; Ikezawa H; Matsuoka T; Tsurutani J
Invest New Drugs; 2020 Oct; 38(5):1540-1549. PubMed ID: 31950374
[TBL] [Abstract][Full Text] [Related]
7. Phase II evaluation of eribulin mesylate (E7389, NSC 707389) in patients with metastatic or recurrent squamous cell carcinoma of the head and neck: Southwest Oncology Group trial S0618.
Arnold SM; Moon J; Williamson SK; Atkins JN; Ou SH; LeBlanc M; Urba SG
Invest New Drugs; 2011 Apr; 29(2):352-9. PubMed ID: 19937365
[TBL] [Abstract][Full Text] [Related]
8. Phase 2 Study of Dose-Dense Doxorubicin and Cyclophosphamide Followed by Eribulin Mesylate With or Without Prophylactic Growth Factor for Adjuvant Treatment of Early-Stage Human Epidermal Growth Factor Receptor 2-Negative Breast Cancer.
Cadoo KA; Kaufman PA; Seidman AD; Chang C; Xing D; Traina TA
Clin Breast Cancer; 2018 Dec; 18(6):433-440.e1. PubMed ID: 29895438
[TBL] [Abstract][Full Text] [Related]
9. Tumour biology, metastatic sites and taxanes sensitivity as determinants of eribulin mesylate efficacy in breast cancer: results from the ERIBEX retrospective, international, multicenter study.
Dell'Ova M; De Maio E; Guiu S; Roca L; Dalenc F; Durigova A; Pinguet F; Bekhtari K; Jacot W; Pouderoux S
BMC Cancer; 2015 Oct; 15():659. PubMed ID: 26449988
[TBL] [Abstract][Full Text] [Related]
10. A phase 1b/2, open-label, dose-escalation, and dose-confirmation study of eribulin mesilate in combination with capecitabine.
Twelves C; Anthoney A; Savulsky CI; Guo M; Reyderman L; Cresti N; Semiglazov V; Timcheva C; Zubairi I; Morrison R; Plummer R; Evans TRJ
Br J Cancer; 2019 Mar; 120(6):579-586. PubMed ID: 30783204
[TBL] [Abstract][Full Text] [Related]
11. Induction therapy with paclitaxel and bevacizumab followed by switch maintenance therapy with eribulin in Japanese patients with HER2-negative metastatic breast cancer: a multicenter, collaborative, open-label, phase II clinical study for the SBCCSG 35 investigators.
Inoue K; Ninomiya J; Saito T; Kimizuka K; Kurosumi M
BMC Cancer; 2018 Jun; 18(1):671. PubMed ID: 29925345
[TBL] [Abstract][Full Text] [Related]
12. Eribulin Treatment in Patients with Liver Metastatic Breast Cancer: Eight Italian Case Reports.
Giordano G; Febbraro A; Quaquarini E; Turletti A; Pedersini R; Raffaele M; Villa F; Rossello R;
Oncology; 2018; 94 Suppl 1(Suppl 1):34-44. PubMed ID: 30041178
[TBL] [Abstract][Full Text] [Related]
13. A phase Ib/II study of eribulin in combination with cyclophosphamide in patients with advanced breast cancer.
Gumusay O; Huppert LA; Magbanua MJM; Wabl CA; Assefa M; Chien AJ; Melisko ME; Majure MC; Moasser M; Park J; Rugo HS
Breast Cancer Res Treat; 2024 Jan; 203(2):197-204. PubMed ID: 37815684
[TBL] [Abstract][Full Text] [Related]
14. Therapeutic Efficacy, Safety and Predictive Indicators of Eribulin Plus Anti-Angiogenic Medicine for Metastatic Breast Cancer.
Zhang J; Wang X; du H; Xue Y
J Coll Physicians Surg Pak; 2024 Jun; 34(6):682-687. PubMed ID: 38840351
[TBL] [Abstract][Full Text] [Related]
15. Evolving approaches to metastatic breast cancer patients pre-treated with anthracycline and taxane.
Saji S
BioDrugs; 2013 Oct; 27(5):469-78. PubMed ID: 23658121
[TBL] [Abstract][Full Text] [Related]
16. Real-world treatment patterns and clinical outcomes in patients treated with eribulin after prior phosphoinositide 3-Kinase inhibitor treatment for metastatic breast cancer.
Goyal RK; Zhang J; Davis KL; Sluga-O'Callaghan M; Kaufman PA
Breast Cancer Res Treat; 2024 May; 205(1):201-210. PubMed ID: 38310616
[TBL] [Abstract][Full Text] [Related]
17. Eribulin for the treatment of metastatic breast cancer: an update on its safety and efficacy.
Doherty MK; Morris PG
Int J Womens Health; 2015; 7():47-58. PubMed ID: 25610001
[TBL] [Abstract][Full Text] [Related]
18. Clinical value of offering multiple chemotherapy lines to a luminal-like metastatic breast cancer: A case report with eribulin.
Valsecchi AA; Paparo J; Pirro V; Manfredi M; Di Maio M; Dionisio R
Tumori; 2023 Dec; 109(6):NP1-NP5. PubMed ID: 36482741
[TBL] [Abstract][Full Text] [Related]
19. Incidence and Resolution of Eribulin-Induced Peripheral Neuropathy (IRENE) in Locally Advanced or Metastatic Breast Cancer: Prospective Cohort Study.
Lück HJ; Schmidt M; Hesse T; Hoffmann O; Heinrich BJ; Park-Simon TW; Grischke EM; Weide R; Müller-Huesmann H; Lüdtke-Heckenkamp K; Fischer D; Zemlin C; Kögel M; Wu J; Schmitz H; Engelbrecht C; Jackisch C
Oncologist; 2023 Dec; 28(12):e1152-e1159. PubMed ID: 37555463
[TBL] [Abstract][Full Text] [Related]
20. Eribulin -- a review of preclinical and clinical studies.
Swami U; Chaudhary I; Ghalib MH; Goel S
Crit Rev Oncol Hematol; 2012 Feb; 81(2):163-84. PubMed ID: 21493087
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
